Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $6.55, but opened at $6.36. Valneva shares last traded at $6.42, with a volume of 2,303 shares.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on VALN shares. HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim lowered their price objective on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, May 8th.
Read Our Latest Research Report on VALN
Valneva Stock Up 5.7%
The stock's 50-day moving average price is $6.11 and its two-hundred day moving average price is $6.29. The stock has a market capitalization of $658.26 million, a PE ratio of -6.50 and a beta of 1.74. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.12 and a current ratio of 2.70.
Valneva (NASDAQ:VALN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.27. The firm had revenue of $51.79 million for the quarter, compared to the consensus estimate of $41.80 million. Valneva had a negative net margin of 43.08% and a negative return on equity of 43.05%. As a group, analysts expect that Valneva SE Sponsored ADR will post 0.13 EPS for the current fiscal year.
Institutional Trading of Valneva
An institutional investor recently bought a new position in Valneva stock. GAMMA Investing LLC bought a new stake in shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,964 shares of the company's stock, valued at approximately $94,000. Institutional investors own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access